Working Group XI – Patient Involvement
Participants at the first meeting of the Working Group, Geneva, 19-20 April 2018
The importance of patient involvement throughout the life cycle of pharmaceutical products, from their development to their use on the market has increasingly been recognized. Patients are now invited to state their perspectives and preferences on new needed medicines, to provide input to regulatory benefit-risk assessments through public hearings and consultations, and to submit adverse reaction reports to pharmacovigilance systems using new technologies such as mobile apps or social media.
Previous CIOMS guidelines have recognized the role of patients as key stakeholders in the safe and effective use of medicines, and some input from patients themselves was obtained for the first time by the CIOMS Working Group (WG) IX when formulating its guidance on Practical Approaches for Risk Minimisation of Medicinal Products.
Working Group objectives
The CIOMS Working Group XI on patient involvement in the development and safe use of medicines was launched in April 2018. It includes participants from patient organizations, industry, regulators, academia and the World Medical Association. These experts are working together to formulate pragmatic Points to Consider in patient involvement. The guidance will provide a comprehensive overview of present knowledge and existing initiatives, and will address a wide range of the remaining challenges and practice gaps. The optimal consideration of patient perspectives will support the safe and effective use of medicines, thereby helping to improve the health of individuals and the public.
- 1st meeting held on 19-20 April 2018, Geneva, Switzerland (minutes)
- 2nd meeting held on 23–24 October 2018, Berlin, Germany (minutes)
- 3rd meeting: To be held on 1-2 May 2019 in Geneva, Switzerland
Open pre-meeting to be held on 30 April 2019
CIOMS Working Groups usually take 2-4 years to finalize their guidance and recommendations. Most groups hold two in-person meetings per year, with telework in between. The groups make use of collaborative efforts and capitalize on existing initiatives in order to provide output that is as comprehensive as possible, does not duplicate other efforts and has added value.
15 - 16 May 2019
5th meeting of Drug-induced Liver Injury Working Group
01 - 02 May 2019
3rd Meeting Working Group XI Patient Involvement in Developmnt/Safe Use Medicines
02 - 03 April 2019
15th Meeting of the Implementation Working Group on MedDRA
27 - 28 February 2019